Anlon Healthcare IPO Day 3: ₹6 Grey-Market Premium Signals Solid Demand
Anlon Healthcare IPO sees ₹6 grey-market premium, 4.75× overall subscription. Retail leads the charge. Allotment and listing dates in focus.
Anlon Healthcare IPO Review: Strong Subscription Amid Market Volatility
The Anlon Healthcare IPO remains impressively subscribed on day 3, with the grey-market premium (GMP) steady at ₹6, despite recent market turbulence. The robust demand signals investor confidence and points toward a potentially smooth listing.
Key Subscription Metrics
♦ By 11:05 AM on bidding day 3, the public issue saw 4.75× overall subscription.
♦ Retail investors surged ahead with a staggering 32.78× subscription.
♦ Non-Institutional Investors (NII) reached 4.72×, while Qualified Institutional Buyers (QIB) just cleared the threshold at 1.01×.
These figures suggest strong interest across the board—with retail investors leading the charge.
Grey-Market Sentiment (GMP) – A Steady Sign
Despite broader market sell-off, the grey-market premium holds at ₹6, unchanged from the previous day. This consistency underscores steady investor sentiment and may provide a psychological uplift for those awaiting listing. The GMP often reflects expectations for listing day pricing.
Market Viewpoints – Catalyst vs. Caution
♦ Sachin Jasuja, Head of Equities & Founding Partner, Centricity WealthTech, highlights “Make in India” and Production-Linked Incentive (PLI) schemes as strong tailwinds for API producers. These policies offer capex support, subsidies, and smoother regulation—factors that could bolster Anlon’s growth and margins.
♦ Shivani Nyati, Head of Wealth at Swastika Investmart, acknowledges Anlon’s specialty API production (notably Loxoprofen) and alignment with global standards, but flags concerns: reliance on one facility in Rajkot and fully valued pricing—especially after a Brazil registration delay that dented FY24 revenue.
What’s Next – Schedule & Expectations
♦ IPO allotment is expected on 30 August 2025. Should this date fall during a weekend, allotments may be pushed to 1 September 2025.
♦ Listing is projected on 3 September 2025, which will deliver the first official pricing signal to investors.
In Summary
Anlon Healthcare’s IPO continues to capture investor attention through strong subscription and unwavering grey-market sentiment. Government incentives and growth prospects present an optimistic backdrop. Yet, concentrated operations and pricing concerns may temper expectations. Watch for the allotment and listing as the next real tests.
